TissenBioFarm reports cell densities comparable to conventional meat in cultivated tissue

TissenBioFarm has reported that it had achieved cultivated meat with cell density equivalent to that of conventional meat, describing the result as a technically realized outcome enabled by its tissue engineering approach. The company shared the update in a public LinkedIn post, linking the development to broader technical debates within the cultivated meat sector.

In the post, the company said cultivated meat was moving beyond hypothetical discussions toward what it described as measurable technical outcomes. “Cultivated meat is no longer at the stage of discussing what might be possible,” TissenBioFarm stated. “It is entering a phase where real, measurable technical outcomes begin to define the next chapter of the industry.”

The statement came against a backdrop of growing skepticism around cultivated meat, following slower-than-anticipated progress and expectations that, in some cases, had outpaced technical realities. TissenBioFarm acknowledged that doubts had increased across the sector but argued that what is technically possible and what has not yet been fully realized should not be treated as the same thing.

A central theme of the post focused on a long-standing question within the industry around cell density in cultivated meat products. “So how many cells are actually in cultivated meat?” the company wrote, noting that the question had been difficult for many cultivated meat companies to answer.

TissenBioFarm said there had been a prevailing belief that achieving cell densities comparable to conventional meat would be extremely difficult. Some critics, the company noted, had argued that cultivated meat products were effectively little more than edible scaffolds rather than true muscle tissue.

The company said it had taken a different approach from the outset. “Cultivated meat is not fundamentally about cells,” TissenBioFarm stated. “At its core, it is about tissue.”

According to the post, the company’s work was grounded in basic biological principles, emphasizing that meat is structured tissue rather than a simple aggregation of individual cells. From that perspective, the company said cultivated meat built from cells should be treated in the same way.

TissenBioFarm described the reported results as the outcome of that approach. “This achievement is the result of that perspective,” the company stated. “Not theory. Not speculation. A technically realized fact.”

The company reported that by controlling initial cell density, it could produce cultivated meat with cell density equivalent to that of real ribeye, as well as cultivated meat containing more than twice the cell density found in conventional meat.

The post did not include quantitative data, third-party validation, or peer-reviewed results, and the company did not disclose the scale at which the reported outcomes were achieved. TissenBioFarm also did not comment on timelines for regulatory submission, commercial production, or cost structure.

Rather than focusing solely on the technical metric itself, the company said the reported achievement shifted the discussion toward downstream value. “Now the question must change,” TissenBioFarm stated. “Not ‘How many cells are in cultivated meat?’ but rather, ‘What new value can cultivated meat with higher cell density than real meat deliver to consumers and to the industry?’”

TissenBioFarm said it intended to answer that question through continued technical development rather than messaging. “TissenBioFarm does not answer this question with words,” the company stated. “We answer it with technology.”

The company also emphasized that progress toward commercially viable cultivated meat would depend on sustained effort across the sector. In its post, TissenBioFarm said that if companies continued to push their respective technologies forward, the cultivated meat products originally envisioned would ultimately become reality.

While cultivated meat companies globally continue to face scrutiny over scalability, cost, and regulatory pathways, technical claims related to tissue structure and cell density remain a key part of the ongoing discussion. TissenBioFarm’s statement added to that conversation, although further disclosure will be required to assess how the reported results translate beyond development settings.